Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Labetalol versus hydralazine for severe pre-eclampsia
PACTR202408671139802Phase 3Recruiting
- Sponsor
- Sakina Ghazali
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in preeclampsia comparing Intravenous labetalol with Intravenous hydralazine (2 arms). Primary endpoints: Number of doses or total dosage required, Unit drop in systolic blood pressure after each dose and 3 more. Started Jun 2022; status: recruiting.
02
Drugs
labetalolhydralazine
03
Conditions
preeclampsia
Beyond the preview
Go deeper on PACTR202408671139802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202408671139802.